alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 251.12 Importer responsibilities. ( a ) The Importer is responsible for: ( 1 ) In accordance with the procedures set forth in § 207.33 of this chapter, proposing an NDC for assignment for each eligible prescription drug imported pursuant to this part;
( 2 ) Examining the Canadian labeling of a sample of each shipment of eligible prescription drugs to verify that the labeling is that of the HPFB-approved drug, and attesting that such examination has been conducted through reports to FDA required under this part;
( 3 ) Screening eligible prescription drugs for evidence that they are adulterated, counterfeit, damaged, tampered with, expired, suspect foreign product, or illegitimate foreign product;
( 4 ) Ensuring the eligible prescription drug is relabeled with the required U.S. labeling, including the container and carton labeling; Prescribing Information; and patient labeling, such as Medication Guides, Instruction for Use documents, and patient package inserts, in accordance with §§ 251.13 and 251.14(d);
( 5 ) Arranging for an entry to be submitted in accordance with § 251.17;
( 6 ) Collecting and submitting the information and documentation to FDA about the imported drug(s) pursuant to section 804(d) of the Federal Food, Drug, and Cosmetic Act, in addition to information about the Foreign Seller, as set forth in § 251.19; and
( 7 ) Submitting the adverse event, field alert, and other reports, and complying with drug recalls, in accordance with § 251.18.
( b ) If the Importer is also relabeling the eligible prescription drug, the Importer must also: ( 1 ) Register with FDA as a repackager or relabeler under section 510(b) of the Federal Food, Drug, and Cosmetic Act, in accordance with § 207.25 of this chapter;
( 2 ) Obtain a labeler code from FDA and propose an NDC for each eligible prescription drug pursuant to § 207.33 of this chapter; and
( 3 ) List each eligible prescription drug pursuant to § 207.53 of this chapter.
( c ) If the Importer is not itself relabeling the eligible prescription drug, the Importer must: ( 1 ) Obtain its own labeler code from FDA under § 207.33(c) of this chapter;
( 2 ) Ensure that the eligible prescription drug incorporates the NDC the Importer proposed for assignment, which must include the Importer's labeler code; and
( 3 ) Ensure that the entity relabeling an eligible prescription drug on its behalf proposes an NDC pursuant to § 207.33 of this chapter and lists each eligible prescription drug pursuant to § 207.53 of this chapter.
EXHIBIT 32
----------




                           CERTIFICATIONS OF
          CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
                  PURSUANT TO 18 U.S.C. SECTION 1350,
               AS ADOPTED PURSUANT TO SECTION 906 OF THE
                      SARBANES-OXLEY ACT OF 2002
          ---------------------------------------------------



     The following statement is provided by the undersigned to accompany
the Quarterly Report on Form 10-Q for the quarter ended March 31, 2011,
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be
deemed filed pursuant to any provision of the Securities Exchange Act of
1934 or any other securities law:

     Each of the undersigned certifies that the foregoing Report on
Form 10-Q fully complies with the requirements of Section 13(a) of the
Securities Exchange Act of 1934 (15 U.S.C. 78m) and that the information
contained in the Form 10-Q fairly presents, in all material respects, the
financial condition and results of operations of ALP Liquidating Trust.




                                       /s/   Gary Nickele
                                       ------------------------------
                                       Gary Nickele
                                       Chief Executive Officer




                                       /s/   Gailen J. Hull
                                       ------------------------------
                                       Gailen J. Hull
                                       Chief Financial Officer and
                                       Principal Accounting Officer
**EXHIBIT
32.2**








**CERTIFICATION
PURSUANT TO**


**18
U.S.C. SECTION 1350,**


**AS
ADOPTED PURSUANT TO**


**SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002**








In
connection with the accompanying Quarterly Report on Form 10-Q of Southwall
Technologies Inc. (the “Company”), for the quarter ended April 3, 2005, as filed
with the Securities and Exchange Commission on the date hereof (the “Report”),
I, Maury Austin, the Chief Financial Officer of the Company, hereby certify
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, that:





1)
    the
      Report fully complies with the requirements of Section 13(a) or 15(d) of
      the Securities Exchange Act of 1934; and




2)
    the
      information contained in the Report fairly presents, in all material
      respects, the financial condition and results of operations of the
      Company.






May
      12, 2005
    By:
    /s/
      Maury AustinMaury
      Austin*Chief
      Financial Officer*








A signed
original of this written statement required by Section 906, or other
document authenticating, acknowledging or otherwise adopting the signature that
appears in typed form within the electronic version of this written statement
required by Section 906, has been provided to the Company and will be
retained by the Company and furnished to the Securities and Exchange Commission
or its staff upon request.





In
accordance with Item 601 of Regulation S-K, this certification is being
“furnished” as Exhibit 32.2 to the Company’s quarterly report and shall not
be deemed “filed” for purposes of Section 18 of the Securities Exchange Act
of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933 or the Exchange Act, except as expressly set forth by
specific reference in such a filing.
Exhibit 23.2

CONSENT OF INDEPENDENT ACCOUNTANTS

We consent to the use in this  Amendment  No. 1 to  Registration  Statement  No.
333-41118 of PSEG Energy  Holdings Inc. on Form S-4 of our report dated June 14,
2000,  appearing  in the  Prospectus,  which  is a  part  of  this  Registration
Statement,  and to the  reference  to us under  the  heading  "Experts"  in such
Prospectus.

Deloitte & Touche LLP

Parsippany, New Jersey
August 31, 2000
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
S.D.W HOLDINGS CORPORATION'S (THE "COMPANY") CONDENSED STATEMENTS OF OPERATIONS
FOR THE YEAR ENDED OCTOBER 1, 1997 AND BALANCE SHEET AS OF OCTOBER 1, 1997 FOUND
IN PAGE 35 AND 36, RESPECTIVELY, OF THE COMPANY'S ANNUAL REPORT ON FORM 10-K
FINANCIAL INFORMATION FOR THE YEAR ENDED OCTOBER 1, 1997.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          OCT-01-1997
<PERIOD-START>                             OCT-03-1996
<PERIOD-END>                               OCT-01-1997
<CASH>                                         180,700
<SECURITIES>                                         0
<RECEIVABLES>                                   45,300
<ALLOWANCES>                                     5,000
<INVENTORY>                                    163,400
<CURRENT-ASSETS>                               437,300
<PP&E>                                       1,165,700
<DEPRECIATION>                                 214,600
<TOTAL-ASSETS>                               1,632,000
<CURRENT-LIABILITIES>                          257,800
<BONDS>                                        739,800
<PREFERRED-MANDATORY>                          103,200
<PREFERRED>                                     56,900
<COMMON>                                             0
<OTHER-SE>                                     312,000
<TOTAL-LIABILITY-AND-EQUITY>                 1,632,000
<SALES>                                      1,405,600
<TOTAL-REVENUES>                             1,405,600
<CGS>                                        1,115,400
<TOTAL-COSTS>                                1,263,300
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              99,000
<INCOME-PRETAX>                                 47,400
<INCOME-TAX>                                    19,200
<INCOME-CONTINUING>                             13,000
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    13,000
<EPS-PRIMARY>                                    49.74 
<EPS-DILUTED>                                    49.74
        

</TABLE>
# LI2018296EN.01000101.xml

| 22.11.2018 | EN | Official Journal of the European Union | LI 296/1 |
| --- | --- | --- | --- |

22.11.2018

EN

Official Journal of the European Union

LI 296/1

---

COMMISSION IMPLEMENTING REGULATION (EU) 2018/1809

of 22 November 2018

amending for the 293rd time Council Regulation (EC) No 881/2002 imposing certain specific restrictive measures directed against certain persons and entities associated with the ISIL (Da'esh) and Al-Qaida organisations

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Council Regulation (EC) No 881/2002 of 27 May 2002 imposing certain specific restrictive measures directed against certain persons and entities associated with the ISIL (Da'esh) and Al-Qaida organisations (1), and in particular Article 7(1)(a) and Article 7a(1) thereof,

Whereas:

| (1) | Annex I to Regulation (EC) No 881/2002 lists the persons, groups and entities covered by the freezing of funds and economic resources under that Regulation. |
| --- | --- |

(1)

Annex I to Regulation (EC) No 881/2002 lists the persons, groups and entities covered by the freezing of funds and economic resources under that Regulation.

| (2) | On 19 November 2018, the Sanctions Committee of the United Nations Security Council decided to add one entry to the list of persons, groups and entities to whom the freezing of funds and economic resources should apply. Annex I to Regulation (EC) No 881/2002 should therefore be amended accordingly. |
| --- | --- |

(2)

On 19 November 2018, the Sanctions Committee of the United Nations Security Council decided to add one entry to the list of persons, groups and entities to whom the freezing of funds and economic resources should apply. Annex I to Regulation (EC) No 881/2002 should therefore be amended accordingly.

| (3) | In order to ensure that the measures provided for in this Regulation are effective it should enter into force immediately, |
| --- | --- |

(3)

In order to ensure that the measures provided for in this Regulation are effective it should enter into force immediately,

HAS ADOPTED THIS REGULATION:

Article 1

Annex I to Regulation (EC) No 881/2002 is amended in accordance with the Annex to this Regulation.

Article 2

This Regulation shall enter into force on the day of its publication in the Official Journal of the European Union.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 22 November 2018.

For the Commission,

On behalf of the President,

Head of the Service for Foreign Policy Instruments

---

(1)  
  OJ L 139, 29.5.2002, p. 9.

1

---

ANNEX

In Annex I to Regulation (EC) No 881/2002 the following entry is added under the heading ‘Natural persons’:

‘HAJJI 'ABD AL-NASIR (aliases Hajji Abdelnasser; Hajji Abd al-Nasr; Taha al-Khuwayt). Date of birth: Between 1965 and 1969. Address: Syrian Arab Republic. Place of birth: Tall 'Afar, Iraq. Nationality: Iraqi. Date of designation referred to in Article 7d(2)(i): 19.11.2018.’

---
#### § 211.111 Time limitations on production.

When appropriate, time limits for the completion of each phase of production shall be established to assure the quality of the drug product. Deviation from established time limits may be acceptable if such deviation does not compromise the quality of the drug product. Such deviation shall be justified and documented.
Editorial Note on Part 312
Editorial Note: Nomenclature changes to part 312 appear at 69 FR 13717, Mar. 24, 2004.

§ 312.38 Withdrawal of an IND. ( a ) At any time a sponsor may withdraw an effective IND without prejudice.
( b ) If an IND is withdrawn, FDA shall be so notified, all clinical investigations conducted under the IND shall be ended, all current investigators notified, and all stocks of the drug returned to the sponsor or otherwise disposed of at the request of the sponsor in accordance with § 312.59.
( c ) If an IND is withdrawn because of a safety reason, the sponsor shall promptly so inform FDA, all participating investigators, and all reviewing Institutional Review Boards, together with the reasons for such withdrawal.
[52 FR 8831, Mar. 19, 1987, as amended at 52 FR 23031, June 17, 1987; 67 FR 9586, Mar. 4, 2002]
§ 530.13 Extralabel use from compounding of approved new animal and approved human drugs. ( a ) This part applies to compounding of a product from approved animal or human drugs by a veterinarian or a pharmacist on the order of a veterinarian within the practice of veterinary medicine. Nothing in this part shall be construed as permitting compounding from bulk drugs.
( b ) Extralabel use from compounding of approved new animal or human drugs is permitted if: ( 1 ) All relevant portions of this part have been complied with;
( 2 ) There is no approved new animal or approved new human drug that, when used as labeled or in conformity with criteria established in this part, will, in the available dosage form and concentration, appropriately treat the condition diagnosed. Compounding from a human drug for use in food-producing animals will not be permitted if an approved animal drug can be used for the compounding;
( 3 ) The compounding is performed by a licensed pharmacist or veterinarian within the scope of a professional practice;
( 4 ) Adequate procedures and processes are followed that ensure the safety and effectiveness of the compounded product;
( 5 ) The scale of the compounding operation is commensurate with the established need for compounded products (e.g., similar to that of comparable practices); and
( 6 ) All relevant State laws relating to the compounding of drugs for use in animals are followed.
( c ) Guidance on the subject of compounding may be found in guidance documents issued by FDA.
# C_2014303EN.01001201.xml

| 8.9.2014 | EN | Official Journal of the European Union | C 303/12 |
| --- | --- | --- | --- |

8.9.2014

EN

Official Journal of the European Union

C 303/12

---

Request for a preliminary ruling from the Tribunal Arbitral Tributário (Centro de Arbitragem Administrativa — CAAD) (Portugal) lodged on 28 May 2014 — Lisboagás GDL, Sociedade Distribuidora de Gás Natural de Lisboa SA v Autoridade Tributária e Aduaneira

(Case C-256/14)

2014/C 303/16

Language of the case: Portuguese

Referring court

Referring court

Tribunal Arbitral Tributário (Centro de Arbitragem Administrativa — CAAD)

Parties to the main proceedings

Parties to the main proceedings

Applicants: Lisboagás GDL, Sociedade Distribuidora de Gás Natural de Lisboa SA

Applicants:

Defendant: Autoridade Tributária e Aduaneira

Defendant:

Questions referred

Questions referred

| 1. | Does EU law preclude the assessment of VAT, when a private undertaking providing infrastructures for the distribution of natural gas passes on to an undertaking acquiring its services, without including any additional amount, the amounts relating to land use taxes paid to the municipalities in which the pipes comprising those infrastructures are located? |
| --- | --- |

1.

Does EU law preclude the assessment of VAT, when a private undertaking providing infrastructures for the distribution of natural gas passes on to an undertaking acquiring its services, without including any additional amount, the amounts relating to land use taxes paid to the municipalities in which the pipes comprising those infrastructures are located?

| 2. | Given that local authorities assess land use taxes in the exercise of their public powers, without including VAT, does EU law preclude the assessment of VAT when the amounts relating to those taxes paid by a private undertaking providing infrastructures for the distribution of natural gas are passed on to an undertaking acquiring its services? |
| --- | --- |

2.

Given that local authorities assess land use taxes in the exercise of their public powers, without including VAT, does EU law preclude the assessment of VAT when the amounts relating to those taxes paid by a private undertaking providing infrastructures for the distribution of natural gas are passed on to an undertaking acquiring its services?

---
EXHIBIT 21

SUBSIDIARIES OF THE REGISTRANT

Parent

The Southern Banc Company, Inc.



|                          |  |                                              |  |                      |  
|------------------------- |  | -------------------------------------------- |  | -------------------- | -
|Subsidiaries (1)          |  | State or Other Jurisdiction of Incorporation |  | Percentage Ownership |  
|The Southern Bank Company |  | United States                                |  | 100                  | %
|First Service Corporation |  | Alabama                                      |  | 100                  | %

---

|(1) | The assets, liabilities and operations of the subsidiaries are included in the consolidated
financial statements attached hereto as an exhibit.
|--- | -----------------------------------------------------------------------------------------------------------------------------------------------



88
<PAGE>   1
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                    FORM 8-K
                                 CURRENT REPORT


                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934



Date of Report (Date of earliest event reported) September 11, 1998

                              THE LOEWEN GROUP INC.
             (Exact name of registrant as specified in its charter)



<TABLE>
<S>                                  <C>                         <C>       
    British Columbia, Canada                 0-18429                      98-0121376
-------------------------------      ------------------------    ---------------------------------
(State or other jurisdiction of      (Commission File Number)    (IRS Employer Identification No.)
         incorporation)
</TABLE>




 4126 Norland Avenue, Burnaby, British Columbia                   V5G 3S8
 ----------------------------------------------                   -------
   (Address of principal executive offices)                      (zip code)



Registrant's telephone number, including area code      604-299-9321



                                       N/A
          (Former name or former address, if changed since last report)




                                                      Exhibit Index is on page 3
                                                                     Page 1 of 4


<PAGE>   2
ITEM 5.        OTHER EVENTS.

Pursuant to Form 8-K, General Instructions F, registrant hereby incorporates by
reference the press release attached hereto as Exhibit 99.


ITEM 7.        FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND 
               EXHIBITS.

<TABLE>
<CAPTION>
               Exhibit No.    Description
               -----------    -----------
<S>                           <C>
               Exhibit 99     The Loewen Group Inc. Press Release dated September 11, 1998
</TABLE>


                                   SIGNATURES

            Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Dated: September 11, 1998

                              THE LOEWEN GROUP INC.



                              By: /s/ PETER S. HYNDMAN
                                 ----------------------------------------
                              Name:  Peter S. Hyndman
                              Title:   Corporate Secretary


<PAGE>   3
                                  EXHIBIT INDEX


<TABLE>
<CAPTION>
                                                                                Sequential
Number         Exhibit                                                          Page Number
------         -------                                                          -----------
<S>            <C>                                                              <C>
99             The Loewen Group Inc.                                                 4
               Press Release dated September 11, 1998
</TABLE>
Exhibit 23.1

                         Consent of Independent Auditors

The Board of Directors
The CIT Group, Inc.

We consent to the use of our report dated January 25, 2001, except as to Note
25, which is dated as of March 13, 2001, relating to the consolidated balance
sheets of The CIT Group, Inc. and subsidiaries as of December 31, 2000 and 1999,
and the related consolidated statements of income, changes in stockholders'
equity, and cash flows for each of the years in the three-year period ended
December 31, 2000, incorporated by reference in the Registration Statement on
Form S-3 of The CIT Group, Inc., which report appears in the December 31, 2000
Annual Report on Form 10-K of The CIT Group, Inc., which is also incorporated by
reference herein, and to the reference to our firm under the heading "Experts"
in the Registration Statement.

KPMG LLP

Short Hills, New Jersey
June 7, 2001
EXHIBIT 32.1

                CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
                    AS ADOPTED PURSUANT TO SECTION 906 OF THE
                           SARBANES-OXLEY ACT OF 2002

In connection  with the  quarterly  report of Avitar,  Inc.  (the  "Company") on
Form10-QSB/A  for the  period  ending  December  31,  2004  as  filed  with  the
Securities and Exchange  Commission on the date hereof (the "Report"),  I, Peter
P. Phildius,  Chief  Executive  Officer of the Company  certify,  pursuant to 18
U.S.C.  Section 1350, as adopted  pursuant to Section 906 of the  Sarbanes-Oxley
Act of 2002, to my knowledge, that:

     (1) The Report  fully  complies  with the  requirements  of  Section  13(a)
or15(d) of the Securities Exchange Act of 1934; and

     (2)  The  information  contained  in the  Report  fairly  presents,  in all
material  respects,  the  financial  condition  and results of operations of the
Company.

Date: March 24, 2005

                                                   /s/ Peter P. Phildius
                                                   ---------------------
                                                   Peter P. Phildius Chief
                                                   Executive Officer